The government has said two deals to invest in the UK’s biotech industry illustrate confidence in its industrial strategy.
MSD (known as Merck in North America) will support a new research centre in London creating around 950 new positions. Germany’s Qiagen will expand its investment in a genomics and diagnostics campus in Manchester.
